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Summary
Eosinophilic endocarditis is a potentially lethal complication of chronic peripheral blood hyper-
eosinophilia. We hypothesized that eosinophil peroxidase (EPO), an abundant eosinophil (EO)
cationic granule protein, promotes eosinophilic endocarditis by binding to negatively charged
endocardium, and there generating cytotoxic oxidants. Using an immunocytochemical technique,
we demonstrated endocardial deposition ofEPO in the heart of a patient with hypereosinophilic
heart disease. Because EPO preferentially oxidizes Br- to hypobromous acid (HOBr) rather than
Cl- to hypochlorous acid (HOCI) at physiologic halide concentrations, we characterized the
Br--dependent toxicity of both activated EOs and purified human EPO towards several types
of endothelial cells and isolated working rat hearts. In RPMI supplemented with 100 1,M Br- ,
phorbol myristate acetate-activated EOs, but not polymorphonuclear leukocytes, caused 1.8-3.6
times as much 51Cr release from four types of endothelial cell monolayers as in RPMI alone.
H202 and purified human EPO, especiallywhen bound to cell surfaces, mediated extraordinarily
potent, completely Br- -dependent cytolysis of endothelial cells that was reversed by peroxidase
inhibitors, HOBr scavengers, and competitive substrates. We further modeled eosinophilic
endocarditis by instilling EPO into the left ventricles of isolated rat hearts, flushing unbound
EPO, then perfusing them with a buffer containing 100 jAM Br - and 1 p,M H202. Acute
congestive heart failure (evidenced by a precipitous decrement in rate pressure product, stroke
volume work, aortic output, and MV02 to 0-33% of control values) ensued over 20 min, which
deletion of EPO, Br- , or H202 completely abrogated. These findings raise the possibility that
EPO bound to endocardial cells might utilize H202 generated either by overlying phagocytes
or endogenous cardiac metabolism along with the virtually inexhaustible supply of Br- from
flowingblood to fuel HOBr-mediated cell damage. By this mechanism, EPO may play an important
role in the pathogenesis of eosinophilic endocarditis.
C
hronic peripheral blood eosinophilia can be complicated
by a morbid and potentially lethal form of endocarditis
characterized by eosinophils (EOs)1 adhering to and infiltrat-
ing the endocardium, mural thrombosis, and embolism (1,
2). Progressive endocardial, then myocardial, damage in eo-
sinophilicendocarditis typically culminates in congestive heart
failure or endomyocardial fibrosis (1, 3). Such hypereosinophilic
heart disease, though rare in Western societies, is estimated
to cause 10-20% of all cardiac deaths in tropical Africa and
'Abbreviations used in this paper. APAAP, alkaline phosphatase-mouse
anti-phosphatase; BAEC, bovine aortic endothelial cells; BENDOC, bovine
endocardial cells; EBSS, Earle's buffered salt solution; ECP, eosinophil
cationic protein; EO, eosinophil; EPO, eosinophil peroxidase; HOBr,
hypobromous acid; HOCI, hypochlorous acid; HUVEC, human umbilical
vein endothelial cells; K-H, Krebs-Henseleit buffer; MBP, major basic
protein; PAEC, porcine aortic endothelial cells; RPP, rate pressure product;
SV, stroke volume.
Southeast Asia, where chronic hypereosinophilia (presum-
ably caused by filariasis or other parasitic infestations) is en-
demic (4). Individuals with hypereosinophilic heart disease
have blood EOs with morphologic and metabolic evidence
of activation (5) as well as high serum levels of potentially
cytotoxic EO granule cationic proteins such as major basic
protein (MBP) (6). This suggests that damage to the en-
dothelial lining of the heart, the endocardium, results from
misapplication of the potent EO antiparasitic armamentarium,
a hypothesis further buttressed by the finding of dense en-
docardial deposition of two EO cationic granule proteins,
MBP and eosinophil cationic protein (ECP), in such patients
(7). Why endocardium in particular should be so much more
afflicted than other endothelial cell beds in hypereosinophilic
states is, however, unknown.
We hypothesized that another EO cationic granule pro-
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in killing helminthic parasites (8), might also contribute to
the pathogenesis of eosinophilic endocarditis by binding to
endocardial cell surfaces and there generating cytotoxic ox-
idants. EPO (unlike MBP and ECP, which appear to rely
mainly on their membrane-perturbant properties to cause cel=lular
disruption [9, 10]) exerts a cytotoxic effect primarily
through its peroxidative catalytic action: utilizing H202 to
oxidize a halide to its corresponding hypohalous acids (11).
Of note, EPOis a peroxidase unique to EOs that, in contrast
to polymorphonuclear myeloperoxidase, preferentially oxi-
dizes Br- to hypobromous acid (HOBr) rather than Cl - to
hypochlorous acid (HOC1) at physiologically relevant (i.e.,
serum) concentrations, where Cl - is in >1,000-fold excess
(100 mM Cl - , 20-100 IAM Br-) (12, 13).
Thepresent investigation defines a potential role forEPO
and its unusual halide preference in promoting eosinophilic
endocarditis by demonstrating potent Br --dependent tox-
icity of activatedEOs andpurified human EPO towards en-
dothelium, endocardium, and isolated working rat hearts.
In the presence of Br -, even a small amount of EPO bound
to the surface of endothelial cells renders them susceptible
to complete destruction by micromolar H202 by localizing
andthereby"focusing" HOBr damage to vulnerable cell com-
ponents. Because endocardial cells coated with EPO could
potentially utilize H202 generated by the active aerobic me-
tabolism ofunderlying myocardial cells to fuel their ownde-
struction, our findings may also explain the proclivity of
hypereosinophilic states to damage endocardium more than
other endothelial beds.
Materials and Methods
Materials. 24-well plates (2 cmz/well) were obtained from
Costar (Cambridge, MA), PMAwas from Consolidated Midland
Corporation (Brewster, NY), and Earle's buffered salt solution
(EBSS), HBSS, Dulbecco's modified MEM, andFCSwere obtained
from Gibco Laboratories (Grand Island, NY). Hetastarch' (6%
hydroxyethyl starch in normal saline) was obtained from DuPont
Co. (Wilmington, DE), and"Crwas from NewEngland Nuclear
(Boston, MA). Sodium bromide, methionine, histidine, guaiacol,
sodium azide, aminotriazole, catalase, BSA, cetrimide (hex-
adecyltrimethylammonium bromide), andhydrogen peroxide (30%
solution) were obtained from SigmaChemical Co. (St. Louis, MO).
Percollwas obtained from Pharmacia Fine Chemicals(Piscataway,
NJ). Murine IgG1 monoclonal AHE-1, which is specific for EPO
(14), was kindly supplied by Dr. Keith Skubitz, University of Min-
nesota (Minneapolis, MN).
Purified human MBP and EPO were kindly provided by Dr.
GeraldJ. Gleich (MayoClinic andResearch Foundation, MN) and
were isolated from eosinophil-richcell suspensions obtained by leu-
kapheresis from patients with hypereosinophilic syndrome, as pre-
viously described (15). Briefly, EO cationic granule proteins were
prepared from aleukapheresisspecimen containing 94% eosinophils
by disrupting the cells with shear stress, solubilizing granules by
free-thawing, and extraction with 0.01 M HCI. Granule extracts
were then chromatographed on a Sephadex G-50 column equil-
ibrated with 0.25 M acetatebuffer (pH 4.3) with 0.15 M NaCl.
The fractions eluting with the void volume were then collected
and further purified to an OD415/280 nm ratio of >0.9 by chroma-
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tography on carboxymethyl Sepharose, as describedby Carlson et
al. (16) . The homogeneity of the EPO prep was further corrobo-
ratedby SDS-PAGE, whichrevealed only two discrete bands (mo-
lecular mass of -78 and -14 kD) that correspond to the large
and small fragments of the EPO molecule. No significant con-
taminants were present. EPO activity was assayed by guaiacol oxi-
dation andconvertedto international units (the amount ofenzyme
that oxidizes i P,mol of electron donor/min at 25°C) (17). The
specific activity of the preparations utilized in the course of these
experiments was 133-250 U/mg protein.
Preparation ofEndothelial Cell Monolaprrs.
￿
Humanumbilicalvein
endothelial cells (HUVEC)were prepared by collagenase treatment
of umbilical cords as previously described (18). Cells were seeded
in 24-well plates (2 cm2/well) (Costar) and used as primary cultures
upon achievingconfluence, usually 5 d after seeding. Porcine and
bovine aortic endothelial cells (PAEC and BAEC) were obtained
by collagenase treatment of fresh porcine aortas as previously de-
scribed (19). Bovine endocardial cells (BENDOC), kindly supplied
by Una Ryan (Miami, FL), were established from cow heart
scrapings. Thebovine andporcine cell lineswere passaged twotimes
weekly anddispensedonto gelatin-coated plastic tissue cultureplates
before seeding 24-well plates forcytotoxicity experiments, described
below, upon achieving confluence.
Immunohistochemical Staining of Heart Sections.
￿
Sections from
formalin-fixed andparaffin-embedded tissue obtained from theheart
of a patient who underwent cardiac transplantation for hyper-
eosinophilic heart diseasewere stained for thepresence ofEPO using
AHE-1mAB specific forEPO andthe alkaline phosphatase-mouse
anti-alkaline phosphatase (APAAP) techniqueas previously described
(14). A 1:100 dilution ofAHE-1 or normal mouseascites (negative
control) wasused in theprimaryantibody incubation. Positive con-
trols were provided by the intense staining of intact eosinophils,
but not otherinflammatory cells present in the heart sections in-
cubated with AHE-1 only (not shown). Normal heart sections
stained with AHE-1 and APAAP showed no deposition . AHE-1
does not bind to MBP, permeabilized neutrophils (and therefore,
myeloperoxidase), cathepsin G, or elastase (14).
EosinophilPurification.
￿
EOs were isolated from peripheral blood
(50-200 m) ofindividuals with mild to moderate peripheral blood
eosinophilia (4-39%), due primarily to allergy. Isolation of EOs
was accomplished usingourmodification (20) of theFMLP-EDTA
techniqueoriginally describedby RobertsandGallin (21). The cell
yieldusingthis techniquewas60-90% ; EO purity was85-99.5%
(mean 94%); contaminating cells were largely PMNs.
s'Cr Release Cytotoxicity Assay.
￿
Endothelial cell toxicity was as-
sayed by measuring specific "Cr release from labeled monolayers
as previously described(20). ForHUVEC, BAEC, andBENDOC,
incubations were for 18 h at 37°C in a 5% C02 and 100% hu-
midified atmosphere; forPAEC, incubations were 2.5 h underiden-
tical conditions. Percent specific "Cr release was calculated as
follows: 100x [(a-c)/(b-c)], wherea = cpm in the supernatant
of any given well, b = totalcounts (pellet + supernatant) in that
well, and c = the mean cpm "spontaneous" release of "Cr into
supernatant buffer offour wells containing labeled monolayers and
EBSS only. Spontaneous releasewas typically 15-20% of the total
counts perwell. All experiments were conducted using triplicate
or quadruplicate determinations of each treatment group. Experi-
ments usingintact EOs utilized 2.5 x 106 cells/well, yielding an
E/T ratio of20-25:1. EO contact with the endothelial cell mono-
layers was then ensuredby gentle centrifugation (50g for 4 min)
of the 24-well plates. Inhibitors, such as azide and aminotriazole,
were addedbefore centrifugation andagonists, such as PMA, after
centrifugation. Forexperiments utilizingpurified human EPO, 200pl of a solution containing 5 x 10 -s M EPO (3.5 ug/ml, 0.5
mU/ml) suspended in HBSS was added to monolayers, whichwere
subsequently incubated 15 min at 37°C. Supernatant buffer con-
taining unbound EPO was then aspirated and discarded, and the
monolayers were subsequently washed two times in 1 ml ofwarm
HBSS. Monolayers not treated with EPO were sham washed and
incubated and washed in a similar fashion.
Hydrogen Peroxide Consumption Assay.
￿
Halide-dependent con-
sumption ofhydrogen peroxide by EPO was assayed by following
the disappearance of H202 spectrophotometrically at 230 nm (22).
Native Chemiluminescence Assay of Purified EPO System.
￿
Na-
tive chemiluminescence assays were performed in clear glass scin-
tillation vials in a scintillation counter (LS 230; Beckman Instru-
ments, Inc., Palo Alto, CA) in the out of coincidence mode. All
reagents, except EPO, were added to the vials that were subsequently
allowed to equilibrate in the dark for 5 min before addition ofEPO
and sequential6-s quantitations oflightemission every 20 s. Reac-
tion mixtures contained final concentrations of 10 mM potassium
phosphate, pH 7.0, 5 x 10-e M EPO, 10 mM H202, and halides
at the indicated concentrations in a final volume of 250 ul. Peroxi-
dase inhibition studies were performed using 1.5 mM sodium azide
or 2 mM aminotriazole.
Isolated and Perfused Rat Heart Studies.
￿
The isolated rat hearts
were perfused as previously described (23), with the following
modifications. Sprague Dawley (male) rats in the range of325-375
gm were anesthetized with 40 mg pentobarbital and anticoagu-
lated with 200 U ofheparin, both administered intraperitoneally.
The animals were intubated and supported on a rodent respirator
(Harvard Apparatus Co., Inc., S. Natick, MA) . The heart was ex-
cised'and immediately immersed in ice-cold Krebs-Henseleit buffer
(K-H; 120 mM NaCl, 6 mM KCI, 1.5 mM KH2CO3, 1.2 mM
MgC12, 1.8 mM CaC12, 97 AM EDTA, and 11 mM glucose). The
heart was then cannulated via the aorta, and retrograde perfusion
was established with oxygenated K-H buffer (95% 02, 5% CO2)
at a column height of 100 cm of H2O within 45 s of cardiectomy.
The hearts were thoroughly flushed to remove residual blood, then
re-immersed in ice cold K-H. 0.5 ml of either cold K-H alone or
buffer containing 10 - ' M EPO (350 ng) was instilled retrogradely
through the aorta, and hypothermic arrest was maintained for 3
min to allow EPO to adhere to the endocardium. Under thesecon-
ditions, -50% (175 ng) of the EPO instilled remained heart as-
sociated, as quantitated by the guaiacol assay. Aortic perfusion with
37°C K-H was then resumed, flushing out nonadherent EPO and
re-establishing regular cardiac contractions.
The left atrial appendage was cannulated and antegrade perfu-
sion started immediately. Baseline determinations of mechanical
function were obtained every 5 min for 15 min before infusion of
H202 commenced. Preload was fixed at 10 cm H2O and afterload
at 85 cm H2O. A pressure transducer (P23Db; Statham, Pasadena,
CA) and a recorder (7402A; Hewlett-Packard Co., Palo Alto, CA)
were used to record pressure and heart rate. Myocardial oxygen
consumption (MV02) was calculated by the difference between the
p02 in the perfusate and the p02 in the coronary effluent, con-
tinuously monitored using a Clarke-type 02 electrode (Yellow
Springs Instrument Co., Yellow Springs, OH). Rate pressure
product (RPP) was calculatedas heart rate times peak systolic pres-
sure, and stroke volume (SV) was calculated as: [(aortic + coro-
nary flow)/heart rate].
Five groups, each containing threehearts, were perfused under
the following conditions: (a) K-H cardioplegia, perfusion with K-
H + 100 AM NaBr (control); (b) EPO cardioplegia, perfusion with
K-H + NaBr + 1 AM H202 (complete system); (c) KH cardi-
oplegia, perfusion with K-H + NaBr + H202 (delete EPO); (d)
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EPO cardioplegia, perfusion with K-H + H202 (delete NaBr);
(e) EPO cardioplegia, perfusion with KH + NaBr (delete H202).
The parameters ofcardiac performance described above were moni-
tored for 20 min after the initiation of the H202 infusion. At the
end ofthe experiment, the hearts were assessed for edemaby meas-
uring wet-to-dry ratios.
Results
To ascertain whether EPO is detectable in the endocardium
of patients with hypereosinophilic heart disease, we stained
sections of heart from such a patient with AHE-1, a mAb
specific for human EPO (14), using the APAAP technique
(14). As expected, EOs, but not other inflammatory cells
present in the sections, stained intensely (not shown). As
shown in Fig. 1, chromogenic substratedeposition (dark) was
absent from the endocardial surface in the section incubated
with normal mouse ascites (left) but prominent in the sec-
tion incubated with AHE-1 (right). Notably, endocardial depo-
sition of EPO was detectable despite the complete absence
of overlying intact EOs. No such deposition was seen in sec-
tions of normal heart (not shown). The substantial amounts
of EPO found in the endocardium of this patient raised the
question of whetherEPO simply adherent to vasculature might
be toxic even in the absence of intact EOs.
First, however, to assess the cytotoxic potential ofbromide-
dependent and EPO-mediated reactions in activated EOs, we
compared the toxicityof PMA-activated EOs in the presence
of physiologic, amounts of Cl - alone, with that in the pres-
ence of physiologic concentrations ofboth Cl - and Br- . We
find that adding 100 PM Br- to RPMI (a "physiologic"
tissue culture medium that otherwise contains 100 mM Cl-
but only trace contaminant amounts of Br-) substantially
increases the toxicity of PMA-stimulated EOs, but not neu-
trophils (PMNs), towards several types ofcultured endothelial
cells (Table 1). As shown on the left, damage to endothelial
monolayers caused by PMAstimulated EOs, as assayed by
s1Cr release, was amplified 1.8-4-fold in RPMI supplemented
with a physiologic concentration of NaBr. The considerable
toxicity causedby PMAactivated EOs in RPMI without added
Br- reflects potential contributions from H202, HOCI
generated from Cl - , or HOBr generated from Br - con-
taminating RPMI (commercial buffer preparations have by
neutron activation analysis been found to contain N5 AM
Br- [12, 13]. Identical results were obtained with Br - sup-
plementation of EBSS, a simple glucose buffer that contains
100 mM Cl- (not shown). Importantly, 100 AM NaBr was
itself completely innocuous to endothelium (not shown). In
contrast to EOs, no bromide enhancement ofkilling was seen
when purified PMNs were the effector cells (Table 1). Of
note, in RPMI alone as well as in RPMI supplemented with
100 AM Br - , PMA-activated EOs were consistently more
toxic than an equivalent number ofPMNS. Because both EOs
(12, 13) and purified human EPO (13) oxidize Br- to HOBr
rather than Cl - to HOC1 at physiologically relevant serum
concentrations (100 mM Cl - and 100 AM Br-) and EPO
is the only EO enzyme known to use Br- as a substrate,
the enhanced endothelial toxicity of PMAactivated EOs in
the presence of Br- is presumably attributable to theirFigure 1 .
￿
Immunocytochemical localization ofEPO in heart of patient with eosinophilic endocarditis. Formaldehyde-fixed and paraffin-embedded
tissue sections from a patient with eosinophilic heart disease were incubated with a 1:100 dilution of normal mouse ascites (left) or AHE-1 murine
mAb specific for human EPO (right), then analyzed for the presence of bound antibody by the APAAP technique. The reaction product is dark . In
both micrographs, the endocardium is on the left and the ventricular lumen on the right. x1,200.
generation ofcytotoxic (seebelow) quantities ofHOBr : 20-40
nmol/106 EOs/h (13, 20) .
If the increased endothelial cell damage caused by activated
EOs in the presence of Br- is attributable solely to EPO,
then purified EPO in isolation should replicate the findings
Table 1.
￿
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in intact EOs. However, because EPO, like several other
membrane-perturbantEO granule proteins, is extremely cat-
ionic (pI > 11 [24]), we first compared the "nonenzymatic"
or inherent toxicity ofEPO towards endothelium with that
ofMBP, a major EO granule component with well-docu-
2-cmz confluent monolayers of BENDOC, BAEC, HUVEC, or PAEC in 24-well Costar tissue culture plates were labeled with 1 UCi s 1Cr/well,
overlaid with 2.5 x 106 EOs or PMNs suspended in 1 ml RPMI (100 mM Cl- , no added Br- ), or RPMI further supplemented with 100 p,M
NaBr (+Br) . Plates were centrifuged 50 g for 4 min to ensure contact between phagocytes and endothelium, then 20 ng/ml PMA was added to
each well . After 18 h (BENDOC, BAEC, HUVEC) or 2.5 h (PAEC) of incubation in a humidified 5% CO2 37°C atmosphere, plates were cen-
trifuged 1,000g for 10 min, supernatant medium and0.1 M NaOH-solubilized monolayers were counted in a gamma counter, and percent specific
s1Cr release was calculated as described in Materials and Methods . The ratio of s'Cr release seen in the presence of Br- (+PMA+Br-) to that in
the absence of Br - (+PMA) was than calculated (+ Br- /-Br -). Data shown are ± SEM.
" Ratio significantly different from 1.0 at p < 0.05 .
Cell type
Percent
+PMA
EOs
"Cr release
+PMA+Br- +Br-/-Br -
Percent
+PMA
PMNs
"Cr release
+PMA+Br - +Br-/-Br -
BENDOC 28.9 ± 2.8 52.0 ± 6.1 1.79 ± 0.12" 14.4 ± 2.1 17.9 ± 3.2 1.24 ± 0.27
BAEC 46.0 ± 3.5 87 .2 ± 3 .7 1 .90 ± 0.12' 17.0 ± 3.1 16.8 ± 1 .9 0.99 ± 0.12
HUVEC 14.9 ± 6.2 26 .7 ± 5.2 1 .79 ± 0.30' 8 .1 ± 3.6 8.3 ± 4 .1 1 .02 ± 0.40
PAEC 4.0±1.2 14.5±2.1 3.66 ± 0.90' ND ND NDm
m
W
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mented toxicity for parasitic (25) and mammalian (26) cells.
These experiments were performed in EBSS buffer in the ab-
sence of Br - and H202 to deprive EPO of both substrates
necessary to fuel catalytic damage. As seen in Fig. 2, on a
molar basis, EPO is at least as toxic as MBP, with 51Cr re-
lease above that in buffer controls detectable at >10 -6 M.
Therefore, in further experiments assaying the peroxidase-
dependent toxicity of EPO, we used concentrations of
<10-7 M, well below its threshold of nonenzymatic
toxicity.
We further characterized the previously reported preferen-
tial oxidation of Br - over Cl- by EPO using purified
human EPO, reagent H202, and halides and by assaying
chemiluminescence and H202 consumption. As shown in
Fig. 3 A, in the presence of 100 mM Cl - and 10 mM H202,
addition of 5 x 10 -8 M EPO causes a scarcely detectable
increase in native (i.e., nonenhanced; EPO can directly oxi-
dize luminol [27]) chemiluminescence, whereas in the pres-
ence of 100 p.M Br- , there is a burst of light output that
exponentially decays. Addition of 100 uM Br - to the 100
mM Cl- vial after EPO has been added elicits a burst of
photon output identical to that seen with Br- alone (not
shown); addition of two potent peroxidase inhibitors, 1.5 mM
Na azide (Fig. 3 A) or 2 mM aminotriazole (not shown),
Figure 3.
￿
Br-specific chemilumi-
nescence and hydrogen peroxide
consumption by EPO. (A) Native
(i.e., nonenhanced) chemilumines-
cence was assayed with an out-of-
coincidence scintillation counter in
clear glass vials containing 10 mM
o~EPO
￿
+ 1oo mM CF
￿
potassium phosphate buffer, pH 7.0,
10 mM H202, and the indicated
halide, with or without 1.5 mm Na
azide in a final volume of 200 pl.
6-s counts of photon emission were
obtainedevery20 s. At the time in-
dicated by the vertical arrow, 10 pl
of 10- 6 M EPO, for a final concen-
tration of5 x 10-e M, was added.
The horizontal line above the x-axis indicates the background ("noise") output of the scintillation counter photomultiplier. (B) H202 consumption
was followed spectrophotometrically at 230 nm in a cuvette containing 10 MM potassium phosphate, pH 7.0, and 4-5 mM H202 in a final volume
of 1 ml. (Open boxes) At the time designated by the middle vertical arrow (+ EPO), 5 x 10-8 M EPO was added, followed by 100 mM KCI (right
arrow, + 100 mM Cl - ). (Filled boxes) At the time indicated by the arrow on the left (+ 100 uM Br- ), 100 1AM KBr was added to a solution con-
taining 5 mM H202 and 5 x 10 - e M EPO in 10 mM potassium phosphate, pH 7.0.
121
￿
Slungaard and Mahoney
Bovine aortic
Bovine endocardial
Humanumbilicalvein
+ 100 pM Br-
Figure 2 .
￿
Comparative toxicity
ofMBPand EPO for endothelium.
Endothelial monolayers ofthe desig-
nated types were 51Cr labeled, in-
cubated with either MBP (A) or
EPO (B) at the indicated concen-
trations for 18 h, then assayed for
percent specific 51Cr release as de
(EPO) (M)
￿
scribed in Materials and Methods.
largely obliterates light output. Similar results were obtained
by analysis of halide-dependent consumption of H202 by
EPO, a necessary concomitant of its catalytic action (Fig. 3
B) . Addition of 5 x 10-8 M EPO to a solution of 4 mM
H202 (open boxes, arrow) did not cause H202 consumption,
showing that EPO lacks catalytic activity. Subsequent addi-
tion of 100 mM Cl - did not cause sustained H202 con-
sumption: 65%d of the abrupt drop in ODmm just after ad-
dition of Cl- is ascribable to dilution artifact. In marked
contrast, addition of 100 14M Br- to H202 and 5 x 10-8
M EPO (filled boxes) engenders brisk, exponentially decaying
H202 consumption, indicating that EPO catalyzes rapid ox-
idation of Br - . These data describe a nearly absolute prefer-
ence of EPO for Br - over Cl- in buffers of physiologic
composition.
Even small amounts ofEPO can mediate extraordinary tox-
icity towards cultured endothelial cells, a toxicity strictly de-
pendent upon the presence of Br- (Fig. 4). Thus, PAEC
monolayers exposed to increasing concentrations of H202 in
EBSS supplemented with 100 14M NaBr showed no signs
of toxicity until -3.3 mM H202, but in the presence of
0.1 U EPO in solution, they were nearly completely lysed
by 33 /AM H202, a 100-fold enhancement (Fig. 4 B, open
boxes). Even greater, 1,000-fold amplification of H202 tOx-
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H202 toxicity for PAEC in the presence of EPO and Br-.
51Cr-labeled PAEC monolayers were overlaid with 200 Al EBSS buffer
(H202 alone) or EBSS with 5 x 10- s M (0.1 U) EPO. After 15 min,
the wells containing EPO were either supplemented with 800 UI EBSS
(+ 0.1 UEPO in solution) or aspirated then washed twice in 1ml EBSS
to remove unboundEPO (+ 0.1 Ucell-bound EPO). Allwellswere made
to 1 ml in either EBSS (100 mM CI-) (A) or EBSS supplemented with
100 aM NaBr (B) before adding the indicated amounts of H202, in-
cubating 2.5 h, then determining percent specific 51Cr release as previ-
ously described. Wells containing cell-bound EPO were further sup-
plementedwith 25 Fig/ml BSAto control forthe supernatantproteinpresent
in wells containing EPO in solution.
icitywasconferredby the 10% of EPO that remains cell bound
(unpublished observation) when monolayers exposed 15 min
to 0.1 U EPO were thoroughly washed to remove unbound
EPO before being exposed to H202 (Fig. 4 B, filled boxes).
This greater sensitivity of monolayers with cell-bound EPO
over those with 10 times as much EPO (750 ng) in solution
was not simply due to the presence of supernatant protein
in the latter, because the buffer for the former was sup-
plemented with 25 alt/ml BSA to control for this factor. Al-
ternatively, in thecase ofEPOin solution,thereis cell-bound
EPO in addition to EPO in supernatant buffer, so at low
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Table 2.
￿
Endothelial Cytotoxicity ofthe EPO/Br/H202
- Br- ￿4 .6 ± 3.1
￿
13.3 ± 6.7
+ 100 ug/ml catalase
￿
-1 .6 ± 1.1
￿
ND
+ 1 mM azide
￿
1.4 ± 2.6
￿
ND
+ 10 mM aminotriazole
￿
-1.1 ± 1.0
￿
3.5 ± 3.0
+ 10 mM guaiacol
￿
20.3 ± 4.8
￿
ND
+ 10 mM histidine
￿
16.8 ± 3.2
￿
ND
+ 10 mM methionine
￿
3.9 ± 2.6
￿
ND
+ 1 mg/ml BSA
￿
59 .7 ± 6.6
￿
ND
2-cm2 monolayers of PAEC or HUVEC endothelial cells were 51Cr la-
beled, then overlaid with 200 pl of EBSS containing 10 -7 M EPO (1.5
,ug or 0.2 guaiacol U) and incubated 15 min, after which supernatant
buffer was aspirated, andthemonolayers were washed twice to remove
unbound EPO. In the complete system (EBSS+EPO+Br - +H202),
1 ml EBSS supplemented with 100 pM NaBr, then 10 -5 M H202 (10
nmol) was added to each monolayer well. The plates were then incu-
bated 2.5 h in a humidified 5% C02 atmosphere at 37°Cbefore deter-
mination of percent specific 51Cr release as described in Materials and
Methods. The indicated reagents were either deleted (-) or added (+)
to the complete system before the addition of H202.
H202 concentrations supernatant EPO could in effect "scav-
enge" added H202, limiting its availability for cell-bound
EPO. Compatible with this interpretation (and further em-
phasizing theamplifiedtoxicity of cell-localized HOBr gener-
ation) is our observation that reagent HOBr added to super-
natant EBSS above PAEC monolayers causes endothelial cell
damage with adose-response curve identical to that of EPO
in solution, not cell-bound EPO (not shown) . Addition of
EPO, whether cell bound or in solution, to PAEC monolayers
in the presence of Cl- alone caused no enhancement what-
soever in their vulnerability to added H202 (Fig. 4 A).
These results show that, in comparison with EPO in solu-
tion, cell surface-bound EPO more efficiently catalyzes le-
thal, strictly Br --dependent damage to endothelium, appar-
ently by localizing andthereby"focusing" damage fueled by
freely diffusible H202 onto critical cellular structures.
The studies summarized in Table 2 show that endothelial
cell damage occurring in the presence of EPO, Br-, and
H202 reflects peroxidative enzymatic activity of EPO rather
than some other, nonenzymatic toxic effect. As seen on the
top line, the complete system (0.2 U EPO, 100 p,M Br - ,
and 10 p,M H202) caused nearly complete lysis of both
PAEC andHUVECmonolayers. Deletion of any one of the
three components almost completely blocked toxicity. Addi-
System: Inhibitor Studies
m 80 -1 Percent specific "Cr release w
Preparation PAEC HUVEC so -
w
V
" H202 alone
O + 0.1 U EPO In solution EBSS +EPO +Br - +H202 75 .1 ± 2.7 79 .9 ± 5.1
40 " + 0.1 U call-bound EPO
v - H202 -2.1 ± 0.8 - 2.0 ± 4.5
w
-EPO 1.3±2.7 2.0±5.1F
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tion of catalase to consume H202, azide and aminotriazole
to inhibit peroxidase enzymatic function, guaiacol to serve
as a competitive substrate for Br - , and the electron-rich
amino acids, histidine, and methionineto "scavenge" hypobro-
mous acid (12) completelyor partially abrogated the toxicity
of the intact system. Interestingly, addition of 1 mg/ml of
BSA, a concentration that nearly completely obliterates cy-
totoxicity in a system in which EPO is free in solution (not
shown), produced a statistically significant but minor decre-
ment in toxicity with cell-bound EPO. These results strongly
suggest that the enzymatic activity of EPO in generating
HOBr accounts for the pronounced toxicity of the complete
system.
To test the relevance of our in vitro cell line observations
to an intact functioning heart, we established an isolated
working rat heart model that mimics the endocardial depo-
sition of EPO demonstrated in tissue sections from human
heart biopsies. In this system, as in cultured endothelial
monolayers, cell-adherent EPO mediates catastrophic damage,
in this case acute heart failure. Fig. 5 shows the time-dependent
variation in four parameters of cardiac function in five ex-
perimental groups of isolated perfused hearts: aortic output
(A), oxygen consumption (MV02, B), SV, (C), and RPP
(D). Hearts whose left ventricles were pre-exposed for 3 min
to 350 ng EPO, flushed thoroughly, monitored for 15 min
to assure stability, then perfused with 1 N.M H202 in K-H
supplemented with 100 /,M Br - (complete system; Fig. 5,
filled boxes) suffered an abrupt decrement in aortic output and
SV as well as a progressive deterioration of MV02 and work
as measured by RPP. By 20 min after the initiation of the
Figure 5. Cardiotoxicity of the
EPO/Br- /H202 system in isolated
working rat hearts. Isolated working
Neelyrat hearts pre-treatedwith instil-
lation of 350 ng EPO or K-H buffer
into theleft ventriclewere perfusedwith
10
￿
20
￿
30
￿
K-H (120 mM CI-) or K-H sup-
MIN
￿
plemented with 100 pM NaBr. Aortic
output (A), oxygen consumption (B),
SV (C), and RPP (D) were then moni-
tored every 5 min for 35 min. At 15
min, as indicatedby the vertical arrows,
the perfusate was supplemented with
1 pM H202 in the appropriate groups.
Br represents hearts not treated with
EPO and simply perfused with Br- -
supplemented K-H. Whether the con-
comitant presence of all three compo-
nents in the complete system (Br+
EPO+H202) was required to cause
cardiotoxicity was assayed by deleting
10
￿
20
￿
3~0
￿
Br - (C1+EPO+H202), EPO (Br+
MIN
￿
H202), or H202 (Br+EPO).
H202 infusion, at the termination of the experiment, these
parameters had all significantly (p < 0.05) decreased to be-
tween 0% (aortic output) and 33% (MV02) that of con-
trol hearts, which were sham pretreated with K-H solution
without EPO during the cardioplegia, then subsequently per-
fused with K-H supplemented with 100 p,M Br- . Br- alone
had no discernible effect on cardiac function (not shown).
No such decrements were seen when any one of the three
components of the complete system (EPO, Br - , or H202)
was deleted (Fig. 5). Hearts treated with the complete system,
but none of the other groups, were edematous, having a
wet/dry ratio of 7.63 ± 0.30 vs. 6.22 ± 0.29 (p < 0.05)
for controls. The failure of heart function occurring with
the complete peroxidase system was not attributable to ar-
rhythmias, as heart ratesremained regular and constant within
a range of 307-336 heart beats/min in all treatment groups
(not shown). Thus, cell-bound EPO, in the presence of 100
ttM Br - and a very low (1 AM) concentration of H202,
produces a syndrome of acute congestive heart failure in iso-
lated working rat hearts.
Discussion
Endothelial cells, interposed as they are between the in-
travascular space and extravascular tissue, bear the brunt of
the attack of overly activated phagocytes. EOs participate,
as do PMNs, in a variety of inflammatory states involving
endothelial cell damage, including vasculitis and pneumonitis
(28). For unclear reasons, however, for PMNs the principal
"shock" organ is the lung (adult respiratory distress syndrome),whereas for EOs the target is the endothelial lining of the
heart, or endocardium (eosinophilic or Loeffler'sendocarditis)
(1, 2). The findings of activated EO oxidative metabolism
(5), high serum levels of MBP and ECP (6), and dense en-
docardial deposition of these same EO cationic granule pro-
teins (7) in individuals with eosinophilic endocarditis impli-
cate inappropriate application of EO cytotoxic effector
mechanisms (intended to kill parasites) in the pathogenesis
of this disorder, but do not explain why the heart suffers dis-
proportionately in hypereosinophilic states.
Our studies suggest a potentially important role for EPO
and HOBr in this process by showing that EPO is bound
to the endocardium of such individuals and that cell-bound
EPO catalyzes from H202 and physiologically relevant con-
centrations of Br- the formation of an oxidant with potent
biologic toxicity for endothelium and functioning hearts. EPO
is present in large amounts (15 ,ug/106 cells) in EOs, ac-
counting for as much as 25% of the protein in EO-specific
granules (27). Although EPO by itself is at least as potent
a toxin for endothelial cells as MBP (Fig. 2), in the catalytic
system with 100 AM Br- , as little as 75 ng (1 pmol) cell-
bound EPO catalyzes from 5 to 10 nmol H202 enough
HOBr to lyse an entire 2-cm2, 200,000-cell monolayer of en-
dothelial cells (Fig. 4). Thus, the amount of EPO present
in only 5,000 EOs could, if completely released and evenly
spread, theoretically destroy 2 cm2 of endothelial cell sur-
face. Though complete release and even spread are improb-
able, we note that absolute EO counts in patients with eo-
sinophilic endocarditis can reach 5 x 10'/ml or more, so
that even partial EO degranulation could over time easily allow
potentially lethal amounts of EPO to accumulate in en-
docardium. By contrast, 130 p,g (10 nmol) of MBP is re-
quired to destroy an equivalent endothelial monolayer (Fig.
2). Therefore, on a molar basis, the EPO system is 10,000
times as toxic for endothelial cells as is MBP. Recent similar
findings by Klebanoff et al. (29) with respect to killing of
schistosomulae further emphasize the remarkable cytotoxic
potency of the EPO/Br - oxidant system.
We recognize that the in vitro models we have developed
to studyeosinophilic endocarditis are not physiologic, as em-
phasized by the unusual rapidity ofendothelial cell death and
heart failure. Several factors probably function in vivo to at-
tenuate the toxicity ofthis oxidant system. First, whole blood
contains large amounts of substances that could potentially
scavenge either H202 (e.g., RBC catalase) or the more reac-
tive HOBr (e.g., proteins, amino acids, and "natural antiox-
idants" such as ascorbate, uric acid, and bilirubin). On the
other hand, when EPO binds to cell surfaces instead of re-
maining in solution, it not only retains (30-34) but actually
increases (15, 35, 36; Fig. 3) its cytotoxic potential in the
presence of suitable halides, including Br- . This increased
cytotoxicity may be due to increased enzymatic activity (35),
or to focusing of oxidant damage to critical cellular struc-
tures with concomitant decreased efficiency of scavengingby
supernatant protein (34, 36). Indeed, by virtue ofits extreme
cationicity and the negative charge of most biologic surfaces,
EPO seems ideally endowed to exploit such a strategy. In-
terestingly, in experiments not shown, we have found that
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treating PAEC monolayers with myeloperoxidase, even in
higher activity amounts than those used in our experiments
with cell-bound EPO (Fig. 4), fails to promote killing by
10 AM H202, a concentration that causes complete destruc-
tion in the presence of Br - and EPO. This difference may
be due in part to the greater cationicity and endothelial cell
binding of EPO in comparison with myeloperoxidase (37),
though peroxidases such as myeloperoxidase are also more
prone to autoinactivation by HOCI than by HOBr (38). We
also note that in our serum-free systems we are attempting
to replicate in hoursdamage that in vivo likely takes months
or even years. It is therefore possible that, despite efficient
scavenging by serum factors, enough HOBr escapes over long
periods of time to cause significant endocardial damage to
accumulate.
Second, though EPO clearly oxidizes Br- rather than
Cl- , serum contains other potential substrates for EPO that
might successfully compete with Br - , such as iodide (I - )
and the pseudohalide thiocyanate (SCN - ). However, I - is
present in submicromolar concentrations that do not affect
HOBr generation by activated EOs (12). We are currently
investigating the utilization of SCN- by EPO. Oxidants
produced by EPO in vivo are in fact probably a complex mix-
ture of HOBr, HOSCN, HOI, and the products of other,
as yet unidentified, nonhalide substrates, the composition of
which is determined by the relative abundance of the poten-
tial substrates. Nevertheless, because of its extreme biologic
potency, even small amounts of HOBr may mediate significant
cytotoxicity without being the sole or even the main reac-
tion product of EPO-catalyzed reactions. Moreover, the prin-
ciple of potent cytotoxic potential conferred by endothelial
cell-bound EPO that is evident in the model we have devel-
oped remains relevant regardless of the substrate involved.
What is the oxidant species responsible for the pronounced
cytopathic efficacy of the EPO/Br - /H202 system? This
system clearly generates an oxidized form of Br - (presum-
ably HOBr in equilibrium with its equivalent oxidation state
species Br2 and OBr-) capable of covalently modifying pro-
teins (12), trimethoxybenzene (13), and fluoresceinate (39) .
Another possibility, however, is highly reactive singlet ox-
ygen, which can be generated in the secondary reaction of
HOBr with H202, the so-called "Allen mechanism": H202
+ HOBr = H+ + Br - + 02(lAs) (40-42) . Unfortu-
nately, though reliable means exist to identify singlet oxygen,
to our knowledge, there exists no scavenger specific for HOBr
or singlet oxygen, both avid electrophiles, to allow dissec-
tion of theirrelative contributions to cell damage. In any case,
singlet oxygen generation, which is kinetically favored in
higher H202 concentrations (41), is less likely in our
EPO/Br-/H202 systems (1-10 AM H202) than in the che-
miluminescence and H202 consumption assays (4-10 mM
H202) or from PMA-activated EOs (42).
Our findings may have relevance for the tendency of
hypereosinophilic endothelial damage to manifest so promi-
nently in the heart. High (up to 15 leg/ml) concentrations
of MBP and ECP circulate in the serum of individuals with
hypereosinophilia (6), but there is no evidence to suggest these
cationic proteins are preferentially deposited in endocardiumas opposed to other endothelial beds. Nonetheless, general-
ized endothelial deposition of EPO might have particularly
adverse effects in the endocardium because EPO is an enzyme
that utilizes Br - , for which there is an inexhaustible supply
in circulating blood, along with H202 to produce a locally
toxic oxidant. Consequently, once bound to an endothelial
surface, EPO is constrained only by the lack of H202 from
producing ongoing cellular damage. Endocardium, in con-
trast to other types of endothelium, is surrounded by inces-
santly active myocardium, a tissue with unusually rapid aer-
obic metabolism. It has been estimated that as much as 5%
of all 02 consumption in heart mitochondria is attributable
to "leakage" of electrons from the electron transport chain
to reduce 02 to O2- , leading to H202 production (43), and
others have documented high rates of myocardial H202
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